Gene‑modified natural killer cells engineered with a chimeric antigen receptor (CAR) to redirect NK recognition and cytotoxicity toward disease-driving immune cells. Upon CAR engagement of the target antigen (not disclosed), the NK cells mediate killing via perforin/granzyme pathways and cytokine-driven immune modulation, aiming to deplete pathogenic autoreactive lymphocytes. Lymphodepletion is used to enhance CAR‑NK engraftment and persistence.